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A B S T R A C T
AngII (angiotensin II) may contribute to cardiovascular risk in obesity via adverse effects on
insulin sensitivity and endothelial function. In the present study, we examined the effects of ARB
(angiotensin receptor blocker) therapy (losartan, 100 mg/day) on insulin sensitivity and endothelial
function in 53 subjects with stage I hypertension, abdominal obesity and impaired fasting glucose.
The study design was a randomized double-blinded parallel design placebo-controlled multi-
centre trial of 8 weeks duration. We used the hyperinsulinaemic–euglycaemic clamp technique
to measure insulin sensitivity (expressed as the ‘M/I’ value) and RH-PAT (reactive hyperaemia-
peripheral arterial tonometry) to measure endothelial function. Additional measures included
HOMA (homoeostasis model assessment)-B, an index of pancreatic β-cell function, and markers
of inflammation [e.g. CRP (C-reactive protein)] and oxidative stress (e.g. F2-isoprostanes). ARB
therapy did not alter insulin sensitivity [5.2 (2.7) pre-treatment and 4.6 (1.6) post-treatment]
compared with placebo therapy [6.1 (2.9) pre-treatment and 5.3 (2.7) post-treatment; P value
not significant], but did improve the HOMA-B compared with placebo therapy (P= 0.05). ARB
therapy also did not change endothelial function [RH-PAT, 2.15 (0.7) pre-treatment and 2.11 (0.7)
post-treatment] compared with placebo therapy [RH-PAT, 1.81 (0.5) pre-treatment and 1.76
(0.7) post-treatment; P value not significant]. Markers of inflammation and oxidative stress were
not significantly changed by ARB therapy. In conclusion, ARB therapy did not alter peripheral
insulin sensitivity or endothelial function in this cohort of patients with essential hypertension,
abdominal obesity and impaired fasting glucose, but did improve pancreatic β-cell function.
Key words: angiotensin II, clinical trial, hypertension, insulin signalling, obesity, vascular function.
Abbreviations: ACE, angiotensin-converting enzyme; ANCOVA, analysis of covariance; AngII, angiotensin II; ARB, angiotensin
receptor blocker; BMI, body mass index; BP, blood pressure; BSA, body surface area; CI, confidence interval; DBP, diastolic BP;
GDR, glucose disposal rate; GDR/I ratio, GDR/mean level of insulin ratio; HOMA, homoeostasis model assessment; HOMA-B,
HOMA of pancreatic β-cell function; HOMA-IR, HOMA of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IRS,
insulin receptor substrate; MCP-1, monocyte chemoattractant protein-1; ox-LDL, oxidized low-density lipoprotein; PVA, pulse
volume amplitude; RH, reactive hyperaemia; RH-PVA, PVA during RH relative to baseline; ROS, reactive oxygen species; SBP,
systolic BP; VCAM-1, vascular cell-adhesion molecule-1.
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INTRODUCTION
Epidemic obesity threatens to reverse progress made
in reducing the burden of cardiovascular disease in
the United States [1]. Two pathophysiological links
underlying obesity and its associated cardiovascular risk
are insulin resistance and endothelial dysfunction. Insulin
resistance, highly prevalent in obesity, predisposes to
diabetes and also adversely affects BP (blood pressure)
and lipid metabolism. Endothelial dysfunction, also
common in obesity, increases susceptibility to vascular
injury by permitting a pro-inflammatory and pro-
thrombotic state. Although often considered as distinct
entities, insulin sensitivity and endothelial function are
in fact integrally linked [2]. Insulin stimulates endothelial
NO production via a signalling pathway homologous to
that of insulin-stimulated glucose transport in skeletal
muscle. In turn, NO activity is essential for effective
insulin-stimulated glucose disposal.
Overactivity of the RAAS (renin–angiotensin–
aldosterone system), and specifically the vasoactive
mediator AngII (angiotensin II), appears to be of
particular importance in the genesis of insulin resistance
and endothelial dysfunction in obesity. AngII is known
to interfere with insulin metabolic signalling at multiple
levels [3,4]. In addition, AngII limits NO bioavailability
by stimulating vascular ROS (reactive oxygen species)
generation [5]. In experimentalmodels, targetingofAngII
improves both insulin resistance and endothelial function
[6,7].
These observations suggest that pharmacological
inhibition of AngII activity may uniquely address
the pathophysiological mechanisms related to excess
cardiovascular risk in obesity. Accordingly, we sought to
examine the effect of angiotensin receptor blockade with
losartan on insulin sensitivity and endothelial function
in hypertensive individuals with abdominal obesity and
impaired fasting glucose.
MATERIALS AND METHODS
Subjects
Eligible subjects comprised non-diabetic men or women,
18–75 years of age, withmild hypertension and taking1
antihypertensive medication. Inclusion criteria included
a screening visit BMI (body mass index) between 30 and
40 kg/m2, waist circumference >40 inches in men or >35
inches in women, and fasting glucose 100 mg/dl and
<126 mg/dl. At the screening visit, subjects’ SBP (systolic
BP) had to be <160 mmHg, and a DBP (diastolic BP) of
<100 mmHg. At the pre-randomization visit, the SBP
had to be 120 and <160 mmHg, and the DBP 80 and
<100 mmHg.
Subjects with known sensitivity or intolerance to
ARBs (angiotensin receptor blockers) or a history of
angio-oedema were not eligible. Other exclusion criteria
included the presence or suspicion of a secondary cause
of hypertension, a history of malignant hypertension,
smoking within the past year, renal impairment, defined
as a serum creatinine >1.5 mg/dl or >2+ proteinuria
by dipstick, the use of antioxidant supplements, an
inability or unwillingness to practice acceptable methods
of birth control, the presence of coronary artery disease,
congestive heart failure or stroke, or any other medical
condition that, in the investigator’s judgment, would alter
the conduct or outcome of the study.
Study design
The present study was an investigator-initiated industry-
sponsored multi-site double-blinded placebo-controlled
randomized parallel design clinical trial. The number
of subjects at each site was: four at the University of
Texas Southwestern Medical Center at Dallas, Dallas,
TX, U.S.A., two at the St. Luke’s Roosevelt Hospital,
New York, NY, U.S.A., six at the Brigham and Women’s
Hospital, Boston, MA, U.S.A., 19 at the Veterans
Administration Health Care System, San Diego, CA,
U.S.A., two at theUniversity ofMiamiDiabetesResearch
Institute, Miami, FL, U.S.A., 14 at the Indiana University
School of Medicine, Indianapolis, IN, U.S.A., two at
the Baylor Clinic, Houston, TX, U.S.A., and four
at the University of Pennsylvania School of Medicine,
Philadelphia, PA, U.S.A.
The study duration was 12 weeks, with 4 weeks of
placebo run-in followed by 8 weeks of double-blind
medication. Participants were randomized to either
losartan (100 mg/day) or placebo in a 1:1 manner.
At the screening visit, subjects gave written informed
consent. Each study site institutional review board
approved the protocol. The study is registered on
ClinicalTrials.gov (http://www.ClinicalTrials.gov) under
the identifier NCT 00675987.
Antihypertensive medication was tapered and discon-
tinued after the screening visit. Once off medication,
subjects began a 4-week single-blind placebo run-in
period. BP and adherence were measured midway and at
the end of the run-in period. Subjects were excluded for
non-compliance at the end of the placebo period (<75%
or >120% of correct number of pills taken) or if the BP
fell outside accepted limits (see above).
Eligible patients then underwent 8 weeks of double-
blind treatment. Endothelial function and insulin
sensitivity were measured on day 1 of treatment and on
the final day (testing visits). Subjects were instructed to
maintain a constant diet throughout the study. Before
all study visits, subjects fasted, avoided exercise for
>12 h, arrived via motorized transportation, did not use
sildenafil, tadalafil or vardenafil for 72 h, and did not
use cold medication, nutritional supplements and niacin
for >24 h. Study medication was not taken on the
morning of a scheduled visit. Study visits all occurred
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before 10.00 hours. For pre-menopausal women, study
visits were scheduled to occur during the follicular phase
of the menstrual cycle. Efforts were made to maintain
a calm environment throughout study visits, and study
measurements were made in a temperature-controlled
room (37 ◦C).
Study measurements
Anthropometric measurements
Body weight and height were measured with the subject
wearing light clothing and no shoes. Waist circumference
was measured at the level of the umbilicus on the bare
abdomen.
BP
A study investigator measured BP using a standard
aneroid sphygmomanometer. All site investigators un-
derwent standardized training in accord with American
Heart Association guidelines [8]. The average of at least
three measurements was taken, and the values were
rounded to the nearest whole number. If a single DBP
reading deviated>5 mmHg from the average, the BP was
considered unstable and the measurements were repeated
on another occasion.
Endothelial function
Endothelium-dependent vasodilation was assessed by
measuring the flow-induced change in digital PVA
(pulse volume amplitude) of the first finger. Digital
PVA was measured using a peripheral arterial tonometer
(EndoPAT; Itamar-Medical). The peripheral arterial
tonometer apparatus comprises a finger-mounted probe
that surrounds the distal phalanx with an electronically
controlled inflatable pressuring air cushion confined
within a rigid external case. The pressure changes within
the probe that accompany pulsatile volume changes
in the finger are fed to a personal computer where
the signal is band-pass-filtered (0.3–30 Hz), amplified,
displayed and stored. The PVA is a measure of the
height of the pulse wave and is proportional to pressure
changes accompanying volume changes within the
probe.
Investigators at each site were trained and had to
demonstrate competence with the technique prior to
subject enrolment. The baseline PVA was measured over
a period of at least 5 min to ensure stability. Thereafter, a
cuff was rapidly inflated to occlusive pressure (at least
50 mmHg >SBP) on the upper arm to induce limb
ischaemia. After exactly 5 min, the cuff was rapidly
deflated and pulse volume measurements were repeated
during this reactive hyperaemic phase. The increase in
PVA during RH (reactive hyperaemia) following cuff
release is in large part caused by NO [9]. Accordingly,
endothelium-dependent vasodilationwas calculated from
the stored digitized data as the ratio of PVA during
RH over a 1-min interval starting 1 min after cuff
deflation and divided by the baseline PVA obtained
over the 1-min interval immediately preceding cuff
inflation. The PVA from the same finger of the
contralateral non-ischaemic hand was used to adjust
for any drift in the magnitude of the signal due to
systemic factors, and the PVA ratio was normalized to
the control contralateral finger [RH-PVA (PVA during
RHrelative to baseline)]. Themeasurement of endothelial
function was repeated once after at least 15 min of
rest, and the average of the two measurements was
calculated.
Insulin sensitivity
A hyperinsulinaemic–euglycaemic clamp was performed
to assess peripheral insulin sensitivity after the
measurement of endothelial function. An intravenous
catheterwas placed in each arm, one for bloodwithdrawal
(the hand) and the other for infusion (the contralateral
forearm). The hand of the blood-withdrawal arm was
placed in a box heated to 50 ◦C to ensure arterialization
of venous blood. The subject’s weight was measured at
each clamp visit, and the BSA (body surface area) was
determined by the Gehan and George equation:
BSA = 0.0235 × (height in cm)0.42246
× (weight in kg)0.51456]
A 2.5 h hyperinsulinaemic–euglycaemic clamp was
performed using a primed continuous insulin infusion.
The priming was 160 m-units/m2 per min for the first
10 min, followed by 80 m-units/m2 per min for 140 min.
Plasma glucose was assessed every 5 min at the bedside,
and 20% dextrose was infused at a variable rate to
maintain plasma glucose of 90 mg/dl +− 5% [10]. Samples
for insulin measurement were obtained in triplicate at
baseline, every 30 min for the first 120 min, and then
every 10 min for the last 30 min. The volume remaining
from the 20% dextrose infusion pump was recorded
every 15 min. Insulin sensitivity (M) was calculated as the
average glucose infusion rate (mg/kg of body weight per
min) over the last 30 min of the clamp. The infusion rate is
approximately equivalent to the GDR (glucose disposal
rate), as endogenous production is suppressed or at least
greatly minimized at this dose of insulin administration
[11]. Steady-state insulin levels varied among subjects
and we therefore calculated the insulin-adjusted insulin
sensitivity or insulin sensitivity index (M/I; where I
is mean level of insulin), which is the GDR/I ratio
during the last 30 min of the clamp multiplied by 200
(arbitrary units). HOMA-IR [HOMA (homoeostasis
model assessment) of insulin resistance], an index that
correlates inversely with peripheral insulin sensitivity,
andHOMA-B (HOMAof β-cell function), an index that
correlates directly with pancreatic β-cell function, were
calculated as described previously [12].
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Additional assays
A fasting venous blood specimen was obtained at the
initial visit for standard safety labs, such as blood
count (LH750; Beckman Coulter), and hepatic and
renal profiles (Modular Biochemical Analyser; Roche
Diagnostics), as well as for glucose and insulin levels
(ADVIA Centaur; Siemens Healthcare Diagnostics).
A urine dipstick pregnancy test was performed at
the initial visit as well as the two testing visits.
At the two testing visits, blood was withdrawn
for measurements of hsCRP (high-sensitivity C-
reactive protein) (Modular P analyser; Roche), VCAM-
1 (vascular cell-adhesion molecule-1) (ELISA; R&D
Systems), MCP-1 (monocyte chemoattractant protein-1)
(ELISA; R&D Systems), ox-LDL (oxidized low-density
lipoprotein) (ELISA; Mercodia), F2-isoprostane (GC–
MS;VanderbiltUniversity,Nashville, TN,U.S.A.) andE-
selectin (ELISA; R&D Systems), and urine was obtained
to assess for the presence of microalbuminuria (Modular
P Analyser; Roche Diagnostics).
Statistical methods
The primary approach to the statistical analysis of the
efficacy data was a modified intention-to-treat approach.
This analysis included all patients who received at least
one dose of the double-blind study drug and had a valid
measurement of insulin sensitivity and/or endothelial
function at baseline and a valid measurement after
baseline. Patients were analysed based on the treatment
group to which they were randomized.
There were two co-primary end points. The first was
the change in peripheral insulin sensitivity after losartan
therapy comparedwith after placebo therapy. The second
was the change in endothelial function after losartan
therapy compared with after placebo therapy. Secondary
end points included the changes in microalbuminuria,
hsCRP, VCAM-1, MCP-1, ox-LDL, F2-isoprostane and
E-selectin after losartan compared with placebo therapy.
It was anticipated that a total enrolment of 60 subjects
randomized into the losartan and placebo groups at
a 1:1 ratio would yield approximately 25 evaluable
subjects in each group. On the basis of two published
studies demonstrating a positive effect of losartan on
insulin resistance [13,14], the losartan treatment effect
was estimated to be 1.38 mg/kg of body weight per min.
Assuming an S.D. of 1.5 mg/kg of body weight per min
and assuming no change in theGDR in the placebo group,
25 evaluable patients per group would then provide 89%
power to detect a significant difference between placebo
and losartan treatment. Losartanwas expected to improve
endothelial function by 24.5% with an S.D. of 21% [15–
18]. Assuming a similar treatment effect size, 25 evaluable
patients per group would provide 98% power to detect
a significant difference between losartan and placebo.
An ANCOVA (analysis of covariance) model was
used to compare the treatments on the primary
Figure 1 CONSORT flow diagram for the trial
and secondary efficacy variables. No adjustment for
multiple hypothesis testing was made. The ANCOVA
included terms for treatment, investigator sites and the
corresponding baseline measurement. Investigator sites
with low enrolment were combined into one or more
groups for analysis. Baseline characteristics are described
asmeans (S.D.) ormedians (S.D.) for parametric and non-
parametric data respectively. The S.D. of the median was
calculated as S.D. = (quartile 3−quartile 1)/1.075.
RESULTS
A total of 171 potential subjects were screened. Of
these, 118 were disqualified for the reasons listed in
Figure 1, leaving 53 subjects who were randomized, 26
to losartan therapy and 27 to placebo. Of those enrolled,
51 subjects completed the trial, 25 in the losartan group
and 26 in the placebo group. Quality review of the
data resulted in three subjects being excluded from
the analysis of insulin sensitivity due to poor quality
insulin clamps. In one subject, the serum insulin
level did not increase from baseline, in one subject
the serum insulin level inexplicably increased ∼5-fold
mid-clamp, and in one subject steady-state was not
achieved. No digital endothelial function study was
considered inadequate. These determinations were made
in a blinded manner prior to locking of the database.
Baseline characteristics of the 53 randomized subjects are
presented by treatment assignment in Table 1.
Insulin sensitivity
At the baseline visit, insulin sensitivity was 5.65 (2.7)
mg/kg of body weight per min among all subjects,
confirming the presence of insulin resistance in the
study population in comparison with historical healthy
populations [19]. Insulin sensitivity at baseline was
not different between the losartan- and placebo-treated
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Table 1 Characteristics of all study participants at screening and by treatment assignment at completion of placebo run-in
Continuous variables as means (S.E.M.) or medians (range). HDL, high-density lipoprotein; n/a, not available.
Screening visit Baseline visit
Characteristic All subjects (n = 53) Placebo (n = 27) Losartan (n = 26)
Age (years) 52.5 (9.5) 53.8 (8.3) 51.1 (10.5)
Sex (female) (n) 26 (49.1 %) 12 (44.4 %) 14 (53.8 %)
Race
White (n) 40 (75.4 %) 24 (88.9 %) 16 (61.5 %)
Black (n) 10 (18.9 %) 1 (3.7 %) 9 (34.6 %)
Other (n) 3 (5.7 %) 2 (7.4 %) 1 (3.8 %)
Taking antihypertensive therapy (n) 1 (1.9 %) 0 1 (3.8 %)
Weight (kg) 101.2 (13.5) 101.6 (14.1) 101.0 (13.7)
BMI (kg/m2) 34.7 (3.8) 34.7 (3.8) 34.8 (3.8)
Waist circumference (cm)* 111.2 (9.9) n/a n/a
SBP (mmHg) 136.0 (10.8) 135.0 (9.6) 136.3 (10.9)
DBP (mmHg) 87.2 (6.4) 86.6 (5.3) 88.7 (5.3)
Heart rate (beats/min) 71.5 (10.6) 74.8 (12.2) 72.4 (9.2)
Potassium (mmol/l) 4.3 (0.3) 4.0 (3.3, 4.7) 4.1 (3.6, 4.9)
Glucose (mmol/l) 104.8 (8.6) 97.5 (1.7) 97.5 (1.7)
Insulin (μ-units/ml) 14.3 (8.0) 10.2 (0.9) 11.7 (1.2)
HOMA-IR 3.8 (2.3) 2.5 (0.2) 2.9 (0.3)
Triacyglycerols (mmol/l) n/a 136.5 (56.0, 309.0) 113.0 (51.0, 235.0)
HDL-cholesterol (mmol/l) n/a 44.0 (22.0, 77.0) 43.0 (31.0, 83.0)
Creatinine (mg/dl) 1.0 (0.2) 0.93 (0.03) 0.88 (0.04)
Urine albumin/creatinine ratio (mg/mmol) n/a 1.22 (0.35) 1.02 (0.18)
*Measured at the screening visit only.
subjects (Table 2). The primary end point, the change in
insulin sensitivity, was not different between the losartan-
treated and the placebo-treated groups.Of note,HOMA-
B tended to increase from baseline in the losartan-treated
group {+ 26.1 [95% CI (confidence interval), − 2.75,
55.0]} and decrease in the placebo-treated group [− 9.6
(95% CI, − 38.8, 19.5)], a difference on the margin of
statistical significance (P= 0.05).
Endothelial function
At the baseline visit, the RH-PVA was 2.0, a result
similar to what has been observed previously in healthy
populations [20]. Baseline endothelial function was not
different between the losartan- and placebo-treated
subjects (Table 3). The change in endothelial function
was not different after losartan therapy compared with
placebo therapy (P value not significant).
Secondary outcomes
In addition to changes in insulin sensitivity and en-
dothelial function, we also examined a series of measures
of inflammation, oxidative stress and endothelial injury
(Table 4). There were no significant changes in any of
these after losartan compared with after placebo therapy.
BP and heart rate
BP was not different between the two treatment
groups at baseline (Table 1). The change in BP after
losartan therapy was not significantly different than after
placebo therapy (Table 5). SBP tended to fall 3.3
(13.0) mmHg in the losartan group and to increase 1.4
(8.4) mmHg in the placebo group. DBP tended to fall
1.5 (8.5) mmHg in the losartan group and to increase 1.2
(7.4) mmHg in the placebo group. There was no
difference in the change in heart rate in the losartan-
compared with the placebo-treated patients.
Renal function and potassium
Baseline renal function, measured as the serum creatinine
level, was within the normal range and did not differ
between the two treatment groups (Table 5). There was
no significant difference in the change in renal function
after losartan compared with placebo therapy. Baseline
and post-treatment serum potassium levels were within
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Table 2 Insulin clamp data in losartan- and placebo-treated patients
Values are means (S.D.) or least-squares mean (95 % CI). P values are a comparison between the groups for a change from the baseline value adjusted for
baseline value and study site.
Parameter Treatment assignment Pre-treatment Post-treatment Change from baseline P value
Fasting glucose (mg/dl) Losartan 97.5 (9.5) 98.2 (6.5) 2.3 (− 1.38, 5.92) 0.69
Placebo 97.5 (8.6) 97.9 (10.5) 1.4 (− 2.26, 5.04)
Fasting insulin (μ-units/ml) Losartan 11.7 (6.1) 14.5 (8.3) 3.5 (0.56, 6.34) 0.07
Placebo 10.2 (4.3) 10.9 (7.2) 0.2 (− 2.69, 3.04)
HOMA-IR Losartan 2.9 (1.7) 3.3 (2.1) 0.7 (− 0.02, 1.41) 0.20
Placebo 2.5 (1.2) 2.7 (2.2) 0.1 (− 0.61, 0.85)
HOMA-B Losartan 127.3 (71) 150.0 (90) 26.1 (− 2.75, 55.0) 0.05
Placebo 108.3 (44) 108.1 (50) − 9.6 (− 38.76, 19.52)
Insulin sensitivity corrected for the
steady-state insulin level [mg/kg of body
weight per min/(μ-units/ml)]
Losartan 5.2 (2.7) 4.5 (1.7) − 0.8 (− 1.62, − 0.07) 0.62
Placebo 6.1 (2.9) 5.3 (2.8) − 0.6 (− 1.39, 0.19)
Table 3 EndoPAT results in losartan- and placebo-treated patients
Values are means (S.D.) or least-squares mean (95 % CI). P values are a comparison between the groups
for a change from the baseline value adjusted for baseline value and study site.
EndoPAT RH Pre-treatment Post-treatment Change from baseline P value
Treatment assignment
Losartan 2.15 (0.7) 2.11 (0.7) − 0.06 (− 0.33, 0.21) 0.31
Placebo 1.81 (0.5) 1.76 (0.7) − 0.23 (− 0.51, 0.04)
Table 4 Blood and urine markers in losartan- and placebo-treated patients
Values are means (S.D.) or least-squares mean (95 % CI), unless otherwise stated. P values are a comparison between the groups for a change from
the baseline value adjusted for baseline value and study site.
Marker Treatment assignment Pre-treatment Post-treatment Change from baseline P value
hsCRP (mg/l)* Losartan 2.6 2.0 − 34 % (− 50 %, − 13 %) 0.07
Placebo 3.3 2.9 − 10 % (− 32 %, 20 %)
VCAM-1 (ng/ml) Losartan 598 585 − 21 (− 70, 28) 0.10
Placebo 663 680 29 (− 20, 79)
MCP-1 (pg/ml) Losartan 335 338 − 24 (− 65, 18) 0.62
Placebo 373 352 − 37 (− 80, 6.8)
oxLDL (units/l) Losartan 50.2 39.8 − 5.5 (− 11.9, 0.9) 0.37
Placebo 41.4 39.8 − 2.0 (− 8.1, 4.1)
F2-isoprostanes (ng/mg of creatinine) Losartan 2.1 3.1 0.9 (− 0.4, 2.2) 0.51
Placebo 1.7 2.5 0.4 (− 0.9, 1.6)
E-selectin (ng/ml) Losartan 41.8 41.6 − 0.6 (− 3.5, 2.3) 0.55
Placebo 43.4 42.7 − 1.6 (− 4.5, 1.3)
Urine albumin/creatine (mg/mmol) Losartan 1.0 1.4 0.2 (− 0.3, 0.8) 0.69
Placebo 1.2 1.5 0.4 (− 0.1, 0.9)
*Geometric means and the geometric mean of the percentage change from baseline are reported.
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Table 5 Select clinical characteristics in losartan- and placebo-treated patients
Values are means (S.D.) or medians (95 % CI). P values are the comparison of the change after losartan therapy with that after placebo therapy, using ANCOVA with
terms for treatment, investigator sites and the corresponding baseline measurement.
Placebo Losartan
Characteristic Pre-treatment Post-treatment Change from baseline Pre-treatment Post-treatment Change from baseline P value
SBP (mmHg) 135.0 (9.8) 136.4 (11.3) 1.4 (8.4) 136.2 (11.1) 132.9 (12.3) − 3.3 (13.0) 0.36
DBP (mmHg) 86.3 (5.3) 87.5 (9.9) 1.2 (7.4) 88.6 (5.4) 87.1 (10.2) − 1.5 (8.5) 0.26
Heart rate (beats/min) 74.8 (12.2) 73.2 (10.5) − 1.7 (11.7) 72.4 (9.2) 71.4 (9.3) − 1.0 (9.9) 0.81
Blood urea nitrogen (mg/dl) 13.5 (6.0, 19.0) 14.0 (6.0, 21.0) 0.5 (− 7.0, 7.0) 12.0 (6.0, 20.0) 12.0 (6.0, 17.0) 0.0 (− 7.0, 4.0) 0.48
Creatinine (mg/dl) 0.9 (0.7, 1.3) 0.9 (0.6, 1.3) 0.0 (− 0.2, 0.1) 0.9 (0.7, 1.4) 0.8 (0.7, 1.4) 0.0 (− 0.1, 0.3) 0.83
Serum potassium (mmol/l) 3.9 (0.3) 4.1 (0.3) 0.2 (0.5) 4.1 (0.3) 4.1 (0.3) 0.0 (0.3) 0.39
the normal range and did not differ between the two
treatment groups.
DISCUSSION
We conducted an 8-week randomized double-blinded
placebo-controlled trial of the ARB losartan (100 mg/
day) in 53 patients with stage I hypertension, abdominal
obesity and impaired fasting glucose, with co-primary
end points of insulin sensitivity and endothelial
dysfunction. We did not observe a significant effect of
ARB therapy on either peripheral insulin sensitivity or
endothelial function compared with placebo therapy.
However, we did observe an improvement in pancreatic
β-cell function attributable to ARB therapy. In addition,
we did not observe an effect of losartan treatment on
a panel of biomarkers of inflammation, oxidative stress
and endothelial injury. Losartan did tend to lower BP
to a similar extent to that observed in a related trial
of 261 patients with essential hypertension randomized
to either losartan or placebo for 8 weeks; however, the
present studywas not powered to detect differences in BP
[21].
Insulin resistance
There is extensive experimental evidence suggesting that
AngII induces insulin resistance. Specifically, AngII
directly interferes with insulin metabolic signalling.
AngII inhibits IRS (insulin receptor substrate)-1 and IRS-
2 associated PI3K (phosphoinositide 3-kinase) activity
and reduces the ability of IRS-1 to associate with
the activated insulin receptor [4,22,23]. AngII also
decreases IRS-1 protein levels in vascular smooth muscle
cells and induces SOCS-3 (suppressor of cytokine
signalling-3), which further inhibits insulin signalling
and insulin-stimulated glucose disposal [3,24]. Thus the
biology supports a potential role for ARB therapy
to improve insulin sensitivity via improved insulin
metabolic signalling.
In the present study, however, losartan did not
improve peripheral insulin sensitivity, asmeasured using a
hyperinsulinaemic–euglycaemic clamp. This differs with
findings in some, but not all previous, reports. Paolissi
et al. [14] reported an ∼25% improvement in GDR
with losartan compared with placebo therapy in 16
mild-to-moderate hypertensive subjects, but, of note in
that study, an unusually large reduction in BP (16/10
mmHg) was attributed to losartan therapy. Moan et al.
[13] described a 27–30% improvement in GDR and
GDR/I with losartan (100 mg/day for 6 weeks), but this
was an uncontrolled study of only five subjects with
severe (DBP115mmHg) hypertension. In a subsequent
controlled study by the same authors involving 20 mildly
hypertensive subjects [25], losartan had no effect on
insulin sensitivity. Interestingly, Moan et al. [25] and
others [26–28] found that losartan, when compared
with calcium channel blocker therapy, improved insulin
sensitivity in hypertensive subjects. Laakso et al.
[29] found that 12 weeks of treatment with losartan
compared with metoprolol in hypertensive patients with
hyperinsulinaemia had no effect on insulin-stimulated
GDR. Finally, Fogari et al. [30–32] have reported three
studies of different populations of hypertensive patients
in which the effect of losartan on insulin-stimulated
GDR was compared with ACE (angiotensin-converting
enzyme) inhibitor therapy; in each trial, losartan failed
to improve GDR, whereas the ACE inhibitor did. Our
present controlled studyofmildhypertensive subjects did
not detect an effect of losartan on insulin sensitivity. On
balance, these trials fail to support the notion that ARB
therapy with losartan in mild hypertension improves
insulin resistance, as measured using the euglycaemic
clamp technique.
This failure to improve insulin sensitivity seems in
conflict with the reported reduction in risk for diabetes
attributed to ARB therapy [33]. This discordance may
be due to the fact that the GDR during a euglycaemic
clamp is mostly determined by skeletal muscle insulin
sensitivity, whereas the ARB therapy may be improving
glycaemia by beneficial effects on the pancreatic
C© The Authors Journal compilation C© 2012 Biochemical Society
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β-cells. Santoro et al. [34], who found that ACE inhibitor
therapy improved glycaemia in essential hypertension
not by improvement in peripheral insulin sensitivity, but
rather by preservation of pancreatic islet β-cell function,
suggested this.
In fact, experimental data suggests that AngII
contributes to β-cell dysfunction via adverse effects on
islet blood flow, and by promoting islet cell fibrosis,
inflammation and oxidative stress [35–37]. Indeed, ARB
therapy was shown to improve early-phase insulin
responses in hypertensive subjects with impaired glucose
tolerance [38]. Our present study confirms that ARB
therapy may preserve β-cell function in hypertension.
Endothelial function
AngII increases vascular ROS generation by induction of
vascular NADPH oxidase [39]. As a consequence of this,
the AngII-infused rat and the rat doubly transgenic for
human renin and angiotensinogen develop hypertension,
vascular oxidative stress and endothelial dysfunction,
each of which is remedied by ARB therapy [5,40].
However, in our present study of obese hypertensive
patients with impaired fasting glucose, losartan therapy
did not improve endothelial function, as assessed by the
change in digital PVA during RH. This is consistent
with some, but not all, published reports. For example,
ACE inhibitor therapy had no effect on forearm
resistance vessel endothelial function compared with
placebo therapy in 24 subjectswith essential hypertension
[41]. In contrast, Koh et al. [42] found that each of
losartan, candesartan and irbesartan improved FMD
(flow-mediated dilation) of the brachial artery compared
with placebo in patients with mild-to-moderate essential
hypertension.We did not detect an effect of ARB therapy
on endothelial function measured by RH-PVA; however,
our subjects’ RH-PVA response prior to interventionwas
similar to that reported previously in healthy subjects
[9,20,43]. Although the present study did not have
an internal control group of healthy individuals, these
historical data suggest that our selection criteria did not
effectively identify a group of subjects with endothelial
dysfunction.
Inflammation and oxidative stress
As a secondary aim of the present study, we examined the
effect of losartan therapy on markers of inflammation,
oxidative stress and endothelial damage. We anticipated
that abnormalities in these biomarkers would provide
insight into the mechanisms of AngII-mediated insulin
resistance and endothelial dysfunction had these findings
been confirmed. For each of these markers there was
biological plausibility [40,44]; however, in the present
study, losartan did not cause a significant improvement
in any of these markers.
Limitations
The results of the present study should be considered
in light of a few study limitations. First, the
hyperinsulinaemic–euglycaemic clamp technique, as
performed, measures skeletal muscle insulin resistance,
but does address β-cell function. Secondly, our sample
size may have been insufficient to detect changes in many
of the examined biomarkers. Thirdly, both Bonetti et al.
[43] and Liu et al. [20] found low interday reproducibility
of the RH-PVA measurements. These reports suggest
that our power calculation, based upon the repeatability
of the brachial artery ultrasound technique, may have
overestimated the power of our sample size. In addition,
although subjects fulfilled entry criteria forBP and fasting
glucose level, average BPs and glucose levels decreased
somewhat (mean values, 135–136/88–89 mmHg and 96–
98 mg/dl respectively) after the placebo run-in period.
Greater baseline abnormalities may be necessary to
observe a positive effect of ARBs on insulin resistance
or endothelial dysfunction.
Conclusions
In summary, we did not observe an effect of ARB therapy
on either insulin sensitivity or endothelial dysfunction in
stage I hypertension characterized by abdominal obesity
and insulin resistance. Our results do suggest though that
ARB therapy improves pancreatic β-cell function in this
population.
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